Method and system for reducing the likelihood of colorectal cancer in a human being
View Patent ↗A system and method for reducing the likelihood of colorectal cancer in a human being includes the modification of an individual's gut microbes by employing a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system to modify only bacterial genes of bacteria that reside in the human gut that are non-homologous to those encompassed in the human genome, and in particular, to administer a therapeutically effective amount of a bacterial formulation comprising F. prausnitzii that has been modified to produce one of alliin or butyrate.
1. A method for reducing the likelihood of colorectal cancer in an individual human being, said method comprising: substantially reducing the human being's resident populations of gut microbes prior to administering a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii ; and providing inulin in an amount sufficient to reduce the pH in the colon of the human being to achieve acidifying of the colon and wherein said bacterial formulation further includes a microbe comprising Veillonella.
2. The method of claim 1 , wherein the Faecalibacterium prausnitzii bacteria employed are isolated from a human being's stool.
3. The method of claim 1 , wherein the Faecalibacterium prausnitzii bacteria employed are from the human being treated.
4. The method of claim 1 , wherein the bacterial formulation comprises bacteria modified via a clustered regularly interspaced short pallindromic repeats (CRISPR) CRISPR associated protein (Cas) system to express p53.
5. The method of claim 1 , further comprising reducing H. pylori populations in the individual human being.
6. The method of claim 1 , wherein the colon is acidified to a degree that intestinal Mg.sup.2+ absorption by the human being is enhanced.
7. The method of claim 1 , wherein the bacterial formulation further comprises a bacterium selected from the group consisting of comprising Chlamydia, Shigella flexneri, Mycoplasma , and H. pylori.
8. The method of claim 1 , wherein the bacterial formulation further comprises Chlamydia bacterium.
9. The method of claim 1 , wherein the bacterial formulation further comprises Shigella flexneri bacterium.
10. The method of claim 1 , wherein the bacterial formulation further comprises Mycoplasma bacterium.
11. The method of claim 1 , wherein the bacterial formulation further comprises H. pylori bacterium.
12. The method of claim 1 , wherein said bacterial formulation further includes a microbe selected from the group consisting of Streptococcus and Treponema.
13. A method for reducing the likelihood of colorectal cancer in an individual human being, said method comprising: substantially reducing the human being's resident populations of gut microbes prior to administering a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii ; and providing inulin in an amount sufficient to reduce the pH in the colon of the human being to achieve acidifying of the colon and wherein said bacterial formulation further includes a microbe comprising Streptococcus.
14. The method of claim 13 , wherein said bacterial formulation further includes a microbe selected from the group consisting of Veillonella and Treponema.
15. The method of claim 13 , wherein the bacterial formulation further comprises a bacterium selected from the group consisting of comprising Chlamydia, Shigella flexneri, Mycoplasma , and H. pylori.
16. The method of claim 13 , wherein the bacterial formulation comprises bacteria modified via a clustered regularly interspaced short pallindromic repeats (CRISPR) CRISPR associated protein (Cas) system to express p53.
17. A method for reducing the likelihood of colorectal cancer in an individual human being, said method comprising: substantially reducing the human being's resident populations of gut microbes prior to administering a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii ; and providing inulin in an amount sufficient to reduce the pH in the colon of the human being to achieve acidifying of the colon, and wherein said bacterial formulation further includes a microbe selected from the group consisting of Prevotella, H. pylori and Treponema , that has been modified by using a CRISPR-Cas or CRISPR-Cpf1 system to excise virulence factor genes.
18. The method of claim 17 , wherein said bacterial formulation further includes a microbe selected from the group consisting of Streptococcus and Veillonella.
19. The method of claim 17 , wherein the bacterial formulation comprises bacteria modified via a clustered regularly interspaced short pallindromic repeats (CRISPR) CRISPR associated protein (Cas) system to express p53.
20. The method of claim 17 , wherein the bacterial formulation further comprises a bacterium selected from the group consisting of comprising Chlamydia, Shigella flexneri, Mycoplasma , and H. pylori.